BRS2017 Final Programme

P122 P130
KEY SUCCESS FACTORS AND DRIVERS WHEN ETHICAL POSITIVE INCENTIVES OPTIONS FOR
LAUNCHING AND DEVELOPING A PROFITABLE KIDNEY DONATION WITHIN THE UK
AND SUSTAINABLE HOME HAEMODIALYSIS Conan Phimister, University of Edinburgh
PROGRAMME
Jean-Philippe Benain, H-Eco P131
QUALITATIVE STUDY OF PARENT EXPERIENCE OF
P123 NEWBORN INFANT DIALYSIS FOR ESTABLISHED
A REVIEW OF A MDT-DELIVERED INTEGRATED RENAL FAILURE TO IMPROVE THE CARE PATHWAY
CONSERVATIVE MANAGEMENT PATHWAY FOR Joanna Woodland, Bristol Royal Hospital for Children
END STAGE KIDNEY DISEASE PATIENTS IN A
TERTIARY REFERRAL CENTRE 2013-2016 P132
Rose Cundiff and Zoe Kime, Leeds Teaching Hospital ROUTINELY COLLECTED PHYSIOLOGICAL PATIENT
Trust OBSERVATIONS (THE NATIONAL EARLY WARNING
SCORE) CAN PREDICT HOSPITAL ACQUIRED
P124 ACUTE KIDNEY INJURY FOLLOWING EMERGENCY
A REVIEW OF PATIENTS CHANGING THEIR MIND MEDICAL ADMISSIONS
ABOUT RECEIVING CONSERVATIVE MANAGEMENT Donald Richardson, University of Bradford
OR RENAL REPLACEMENT THERAPY FOR END
STAGE KIDNEY DISEASE IN A TERTIARY REFERRAL P133
CENTRE 2013-2016 GENETIC VARIANTS OFIL-1R1 AND IL-1R2GENES
Andrew Mooney, St James’s University Hospital AND IGA NEPHROPATHYRISKIN THE HAN CHINESE
POPULATION
P125 Jiali Wei, Hainan General Hospital
THE ROLE OF DOMICILIARY VISITS IN INCREASING
ACCESS TO RENAL SUPPORTIVE CARE P134
Joanne Sloan, NHS Tayside CULTURALLY APPROPRIATE INNOVATIVE CARE IN
THE KIMBERLEY
P126 Melanie McNiece, Kimberley Aboriginal Medical Services
THE VIRTUAL TREE OF REMEMBRANCE
Haydn Hamm, Royal Derby Hospital q INNOVATIONS IN PRACTICE, INFECTION
CONTROL AND SERVICE DELIVERY
q PAEDIATRICS, EPIDEMIOLOGY AND
MISCELLANEOUS P135
A SINGLE CENTRE QUALITY IMPROVEMENT PILOT
P127 TO EVALUATE A NOVEL, PERSONALISED, NURSE
OUTCOMES OF IMMUNOSUPPRESSION LED PATHWAY FOR PATIENTS COMMENCING
WITHDRAWAL IN PATIENTS WITH ANCA- HAEMODIALYSIS
ASSOCIATED VASCULITIS Vicky Ashworth, Royal Liverpool and Broadgreen
Amy Livesey, Queen Elizabeth Hospital Birmingham University Hospital

P128 P136
WHAT DO I TELL THE CHILDREN ABOUT MY SUCCESSFUL INTRODUCTION OF PROGRAMME OF
KIDNEY DISEASE: A RESOURCE FOR ADULTS TO INFLUENZA VACCINATION FOR HAEMODIALYSIS
INFORM CHILDREN PATIENTS
Victoria Hanson, Guys and St Thomas’ NHS Foundation Clara Day, Queen Elizabeth Hospital Birmingham
Trust
P137
P129 TOLVAPTAN: A NOVEL THERAPY FROM CLINICAL
ADHERENCE BEHAVIOUR IN HAEMODIALYSIS TRIAL TO CLINICAL PRACTICE
PATIENTS’ PRE AND POST RECEIPT OF A KIDNEY Sarah Borrows, Queen Elizabeth Hospital Birmingham
TRANSPLANT: A RETROSPECTIVE STUDY
Abigail Hucker, University of Hertfordshire

26-28 April 2017 | Nottingham 51

P138 P147
PREVENTING THE SPREAD OF CARBAPENAMASE PERITONEAL DIALYSIS TRAINING PROGRAMME:
PRODUCING ENTEROBACTERIACEAE (CPE) IN THE THE DEVELOPMENT OF A PATIENT TEACHING
DIALYSIS UNIT PROGRAMME, EDUCATION PACKAGE AND
Maggie Higginbotham, York Hospital COMPETENCY CHECKLIST
Jill Willis, Royal Derby Hospital
P139
RECRUITMENT AND RETENTION OF RENAL P148
NURSING STAFF - CHALLENGES AND ENGAGING PATIENTS IN CHOOSING RESEARCH
OPPORTUNITIES IN AN NHS TRUST PRIORITIES – PATIENT SURVEY 2016
Sarah Brand, Nottingham University Hospitals Trust Sarah-Louise Harwood, Kidney Research UK

P140 P149

THE NURSE-LED SERVICE FOR MANAGEMENT OF RENAL PEER SUPPORT BUDDY PROGRAMME:
PATIENTS WITH RARE RENAL METABOLIC DISEASES DEVELOPING A PATIENT-LED SUPPORT SERVICE
Michelle Lowe, Queen Elizabeth Hospital Birmingham Emma Coyne, Nottingham University Hospitals NHS Trust

P141 P150

RENAL ELDERLY CARE NURSING SUPPORT: IMPACT BROADENING OUR METHODS FOR PROVIDING
ON DIALYSIS STAFF WORKING PATTERNS AT 1-YEAR PATIENT INFORMATION
Seema Singh, Hammersmith Hospital Wendy Brown, Imperial College NHS Healthcare Trust

P142 P151
IS THE PRE DIALYSIS INFORMATION CURRENTLY
GIVEN REFLECTIVE OF THE DIALYSIS PATIENT’S SIX MONTHS OF LONGER HAEMODIALYSIS LEADS
NEEDS? TO BETTER QUALITY OF LIFE COMPARED TO
Michelle Wagstaff, Kings Mill Satellite Dialysis Unit CONVENTIONAL SESSIONS: RESULTS FROM A
NON-RANDOMISED TRIAL
q PATIENT EDUCATION/INVOLVEMENT Darren Churchward, Department of Infection, Immunity
and Inflammation, University of Leicester

P143 q QUALITY IMPROVEMENT AND INNOVATION
EDUCATION AND MANAGEMENT OF RENAL
PATIENTS IN REMOTE COMMUNITIES OF THE P152
KIMBERLEY’S, WESTERN AUSTRALIA IDENTIFYING A RENAL SERVICE NEED FOR
Brett Carruthers, Kununurra Renal Services OCCUPATIONAL THERAPY (OT) INPUT TO OPTIMISE
INDEPENDENCE, FUNCTION AND QUALITY OF LIFE
P144 OF HOME HAEMODIALYSIS PATIENTS
EFFECTIVE SUPPORT AND INVOLVEMENT OF Joanne Hamilton, Derby Teaching Hospitals NHS
REMOTE ABORIGINAL PEOPLE THROUGH A Foundation Trust
PROCESS OF INFORMED CONSENT
Felicity Stewart, Kimberley Aboriginal Medical Service - P153
Kimberley Renal Services SAFETY HUDDLES ON A PAEDIATRIC NEPHROLOGY
WARD; QUALITY IMPROVEMENT IN 10 MINS?
P145 Andrew Lunn, Nottingham Children’s Hospital
PATIENTS AS PARTNERS: AN EXPLORATION OF
COLLABORATIVE RESEARCH TEAM WORKING AND P154
THE ROLE OF THE LAY RESEARCHER AN ALKALINE DIET CAN INDUCE REGRESSION OF CKD
Jane Smiddy, University of Hertfordshire Caroline Passey, Wessex Renal and Transplant Unit

P146 q CKD, ANEAMIA AND MINERAL BONE DISEASE

IS THERE A NEED FOR A SPECIFIC PERITONEAL P155
DIALYSIS (PD) ASSESSMENT TOOL TO IMPROVE CONSISTENCY OF RECOMMENDATIONS FOR
THE RATE OF TRAINING FAILURES IN AN AGING DRUG DOSE ADJUSTMENT IN RENAL IMPAIRMENT
DIALYSIS POPULATION? Andrew Findley, Lister Hospital
Paul Waddington, Baxter Healthcare

52 British Renal Society Conference

P156 P164
BODY COMPOSITION INFLUENCES AUTOMATICALLY DETECTING AKI EVENTS FROM
ERYTHROPOIETIN RESPONSE AND HAEMOGLOBIN PRIMARY CARE RECORDS
STATUS AMONG HAEMODIALYSIS PATIENTS IN Simon Bull, University of Surrey
TANZANIA: A SINGLE CENTRE CROSS-SECTIONAL
STUDY P165
Nyangi Gityamwi, University of Surrey ACT-AKI - ASSESS CONTRIBUTING FACTORS FOR
TIMELY TREATMENT FOR ACUTE KIDNEY INJURY.
P157 DEFINITION: INEQUALITIES IN EDUCATION FOR
IRON ISOMALTOSIDE 1000 5% (DIAFER®) ACUTE KIDNEY DISEASE
COMPARED TO IRON SUCROSE (VENOFER) IN Adam Vallins, Royal Derby Hospital
PATIENTS WITH HAEMODIALYSIS DEPENDENT
KIDNEY DISEASE P167
Richard Cooper, Hull and East Yorkshire NHS Trust A QUALITY IMPROVEMENT APPROACH TO
ENGINEERING AN EMBEDDED PHARMACIST ROLE
P158 IN AKI MANAGEMENT IN SECONDARY CARE
SURGICAL APPROACH AND THE IMPACTS ON PTH Elizabeth Lamerton, Salford Royal NHS Foundation
AND HYPOCALCAEMIA IN THE MANAGEMENT OF Trust
SECONDARY HYPERPARATHYROIDISM
Max Richardson, Sheffield Teaching Hospitals P168
IS AKI TRULY THE CAUSE OF DEATH?
P159 Maximilian Wills, Lister Hospital
AN EXAMPLE OF THE IMPACT THAT RENAL
REGISTRY RESULTS CAN HAVE ON DIETETIC P169
PRACTICE IN THE MANAGEMENT OF PATIENT IMPROVED ACUTE KIDNEY INJURY (AKI)
BONE PROFILES KNOWLEDGE AND AWARENESS AFTER
Stuart Gerty, Royal Cornwall Hospitals NHS COMPREHENSIVE EDUCATIONAL PROGRAMME IN
PRIMARY CARE
P160 Joanna Mckinnell, Derby Teaching Hospitals
BONE AND MINERAL DISEASE MANAGEMENT IN
HAEMODIALYSIS -- HOW SHOULD TEAMS WORK? P170
Louise Wells, York Hospital LOWER GI ENDOSCOPY AND AKI RISK IN PATIENTS
with ckd
P161 Michael Avoseh, Queens Medical Centre
A SURVEY ON CLINICIANS’ VIEWS ON AUTOMATED
ELECTRONIC ALERT SYSTEM FOR ACUTE KIDNEY P171
INJURY AND ITS INFLUENCE ON CLINICAL PREDICTORS OF ACUTE KIDNEY INJURY IN
PRACTICE PATTERNS UNSELECTED ADULT HOSPITALISATIONS
Khai Ping Ng, Russells Hall Hospital Richard Bigger, University of Bristol Medical School

q ACUTE KIDNEY INJURY P172

P162 THE IMPACT OF AN EDUCATIONAL WORKSHOP
MANDATORY ACUTE KIDNEY INJURY ON ACUTE KIDNEY INJURY ON CARE HOME
INFORMATION FOR DISCHARGE LETTERS - STAFF’S KNOWLEDGE OF THE CONDITION
RESULTS FROM A DISTRICT GENERAL HOSPITAL AND EFFECTS ON THE NUMBER OF RESIDENTS
Boavojuvie Oseya, John Wells Renal Unit, Leicester DEVELOPING ACUTE KIDNEY INJURY.
James Nicholl, Queens University Belfast

P163

PRESCRIBING PATTERNS AT THE TIME OF AKI:
OPPORTUNITIES TO IMPROVE CARE
Sue Shaw, Royal Derby Hospital

26-28 April 2017 | Nottingham 53

Exhibition layout These companies have supported this meeting
by way of purchase of stand space only

54 British Renal Society Conference

Exhibitor profiles The following companies have supported this
meeting by way of purchase of stand space only

ACIME UK Limited

Based in the north of France, we design, produce and sell mobile units for transport
and care of patients inside hospitals and private clinics.

Our wide range of renal products includes care armchairs, transfer chairs,
examination couches, and screens that allow good infection control, offer
enhanced ergonomics, comfort, safety and ease of use, and promote effective risk
management. All include a wide range of features, options and accessories to meet
a variety of clinical needs and budgets.

• Innovating products manufactured and designed on site.
• 25-year-experience
• A dynamic team close to you
• Short delivery times

Alexion

Alexion is a global biopharmaceutical company focused on developing and
delivering life-transforming therapies for patients with devastating and rare diseases.

Auriga Services Limited

Auriga Services is a not for profit organisation supporting companies and organisations to
help their most vulnerable clients to address their financial needs and well-being.
When Auriga was established our core service was administering Trust Funds for three
of the major water utility companies in the UK, those being Severn Trent Water, United
Utilities Water and Thames Water.

Over the last few years, we developed a high quality personalised welfare and debt advice
service to provide that support to those that require further assistance.

This has led to a partnership with University Hospitals Birmingham, where our Welfare
Advisers visit renal hubs across the West Midlands to help Kidney Dialysis patients and
their families with welfare and debt advice.

Our advisers are able to assist with a wide range of services such as applications to Trust
Funds, income maximisation, benefits checks and realisation, debt advice, appeals and
tribunal processes including representation where appropriate plus much more.

To date we have helped 1.5 million people to reduce their financial hardship working
closely with our clients to meet our main objective of ‘Changing Lives Every Day’.

By 2020, Auriga will have helped two million people.

26-28 April 2017 | Nottingham 55

B Braun

The B Braun group is one of the world’s fastest growing healthcare companies. B
Braun Avitum UK provides the NHS with a complete solution for Haemodialysis
products and services. Today we operate 15 UK dialysis centers and are a trusted
partner for haemodialysis in the hospital, satellite unit and at home.

We are proud to show our newest addition to the dialysis machine range, the
Dialog IQ. The machine’s intelligent system, Biologic Fusion, allows monitoring of
two biologic inputs to support patient stability on dialysis.

B.Braun Avitum provides a full home haemodialysis (HHD) service, everything
from efficient patient management and delivery service, to the required clinical
and technical support. Our HHD programme is tailored to each Trust’s specific
requirements.

We manufacture, install and maintain water treatment systems. The B.Braun
Aquaboss systems benefit from an array of innovative features such as the dead
space free loops, eco impulse backwash and steam sterilisation.

We would like to welcome you to the B Braun stand to discover more about B Braun
Avitum UK’s products and services.

British Kidney Patient Association

“The British Kidney Patient Association is the UK’s leading kidney patient support
charity. For over 40 years we have been providing help and support to kidney
patients and working to improve health and care services for patients and their
families. With over 100 patients supported every week, and around £3million
invested every year in research, funding health and care professionals and improving
hospital services, we are committed to improving the quality of life for everyone
affected by kidney disease.

How we help

• Providing grants to help patients in times of financial hardship
• Providing information, advice, counselling and patient support services
• Funding much needed holidays and respite breaks
• Campaigning to inform policy and practice that improves the lives and choices

of kidney patients
• Funding kidney units to improve services and patient care
• Commissioning patient centred research to improve health and care services

Boehringer Ingelheim

Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies.
Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates presently
with a total of some 50,000 employees worldwide. The focus of the family-owned
company, founded in 1885, is on researching, developing, manufacturing and
marketing new medications of high therapeutic value for human and veterinary
medicine.

56 British Renal Society Conference

Chiesi Limited

Chiesi Limited is the UK affiliate of the international, privately-owned pharmaceutical
company, Chiesi Farmaceutici S.p.A based in Parma, Italy. Chiesi is dedicated to the
research, development and sales of innovative, therapeutic prescription medicines
in the fields of respiratory medicine, neonatology, transplant medicine and rare
diseases.

The Company, founded in 1935, now spans the globe, employing more than 4,500
people in 26 affiliates worldwide, and sells its products in more than 70 countries.

We embrace innovation which is a constant driver to our continued success.
Products wholly, or partially, developed by Chiesi account for three quarters of
our sales, and our investment in Research and Development currently stands at
€302 million – more than 20% of our revenue. Chiesi ‘firsts’ include the first stem
cell product approved in Europe and new options for serious genetic diseases. We
applied for 18 new patents in 2015 alone.

In the area of transplantation, Chiesi has recently launched a different formulation
of a tried and trusted immunosuppressant. This product forms part of a growing
Special Care portfolio, for which Chiesi has strong ambitions to develop and acquire
new medicines.

Chiesi is also committed to providing education and support to transplant specialists
and patients throughout the UK via a number of organisations.

Fresenius Medical Care

Fresenius Medical Care is the world’s leading provider of products and services
for people with chronic kidney failure. Around 3 million patients with this disease
worldwide regularly undergo dialysis treatment. Dialysis is a vital blood cleansing
procedure that substitutes the function of the kidney in case of kidney failure.

We care for more than 308,000 patients in our global network of more than 3,600
dialysis clinics. At the same time, we operate 37 production sites on all continents,
to provide dialysis products such as dialysis machines, dialyzers and related
disposables.

Our strategy is geared toward sustainable growth. We aim to continuously improve
the quality of life of patients with kidney disease by offering innovative products and
treatment concepts of the highest quality.

26-28 April 2017 | Nottingham 57

Hemodia

Hemodia is a dynamic European medical company. With headquarters based in
Toulouse, France, and various international operations it employs about 300 people.
Hemodia has specialised in Dialysis Procedure Packs since 1985 and provides a total
in-house solution (manufacturing, sterilisation and delivery). Our expertise in the
area has allowed Hemodia to become a market leader, with 70% market share in
dialysis procedure packs in France for example.

Hemodia’s product offering is based on a catalogue of more than 650 carefully
sourced items and consumables. Our purpose is to deliver long term quality and
reliability to customers and dialysis patients. Hemodia’s control of its manufacturing
processes and logistics capabilities deliver value through waste reduction and cost
savings. The customised product offer as well as reactivity and reliability through
the supply chain brings flexibility to our offer. The development of Hemodia UK is
now in full swing and is supported by our Procedure Packs division as well as our five
manufacturing plants. Come find out how Hemodia can help deliver value to your
service and exchange with the team at the 2017 BRS Conference!

Immucor

Founded in 1982, Immucor is a global leader of transfusion and transplantation
diagnostics. For transfusions, Immucor offers the broadest line of serological
products, including traditional and unique specialty reagents, Capture® technology,
and Scalable Solutions for automating immunohaematology testing. Our BioArray
molecular immunohaematology assays provide state-of-the-art technology for pre-
transfusion compatibility testing. For transplants, our LIFECODES products bring
a market-leading position in HLA testing for donor-patient compatibility. We are
leading the way in post-transplant monitoring with our innovative kSORT assay for
kidneys.

Our transplant diagnostics division provides molecular and antibody-based assays
for HLA compatibility between donors and recipients. Laboratories all over the
world use Immucor products as a part of determining the best path forward for a
transplant recipient and lowering the probability of rejection. Developing tests to
help manage patients post-transplant is our focused commitment. By providing
clinicians better tools, we can help change the practice of transplant medicine.

Independence Products Limited

Independence Products is an established UK supplier of specialist prescription
products for both Haemodialysis and Peritoneal Dialysis patients. With infection
being one of the main concerns for dialysis patients and nurses, Independence
Products provide waterproof pouches to protect the integrity of the catheter
insertion site allowing patients to shower or swim carefree. We take pride in
supplying high quality, easily obtainable and cost effective products that allow
patients to resume their day to day routine without the constant worry of infection
and the possibility of a hospital admission.

Our products are available on prescription and can be obtained through Pharmacies,
Dispensing Appliance Contractors and various Pharmaceutical and Surgical
Wholesalers.

58 British Renal Society Conference

Journal of Kidney Care

Journal of Kidney Care (JKC) is the essential bi-monthly peer-reviewed publication
for all members of the multidisciplinary renal team. Through clinical papers and
original research it covers several clinical areas of renal medicine, such as dialysis,
transplantation, diabetes, anaemia, pharmacy and nutrition. Every issue of the
journal will have a clinical focus on one of these key aspects of kidney care.

Formerly Journal of Renal Nursing, JKC was relaunched to reflect the
multidisciplinary nature of kidney care and the wide range of the journal’s content.
JKC’s content is aimed at doctors, nurses, healthcare assistants, dietitians,
pharmacists, physiotherapists, paediatric specialists, clinical technologists, social
workers, vascular access specialists, and transplant surgeons and coordinators
specialising in kidney care.

Kidney Research UK

We are the UK’s leading kidney research charity and we believe that everybody has
a right to a life free of kidney disease. We are pioneers in our field. For decades our
developments in treatments, better information for patients and raising vital public
awareness have been saving lives. Today, our work is more essential than ever.

Our research saves lives and gives people hope. Every year an estimated 64,000 people
with kidney failure are alive today because of the advances we have directly contributed
to and through our research breakthroughs more kidney patients and their families have
the chance of a better life.

We develop kidney researchers. We invest in the training and support of many allied
health professionals, scientists and doctors within the renal field throughout the UK.
Many of these individuals have gone on to make major advances in the understanding
of the causes of kidney disease as well as the successful development of better
approaches to its treatment.

Over £6 million invested. Thanks to our amazing supporters we were able to invest £6
million into renal research in the last year but sadly, we have to turn away around half of
the excellent research proposals that we want to support.

Engaging with patients, policy makers and tackling inequality. We engage with and
influence parliamentarians and policy makers through our proactive public affairs
programme. We believe in placing patients at the heart of research and are very active
in presenting the patient view to NICE, the SMC and AWMSG. Our health equalities
programme has reached around 30,000 people in the Black, Asian and Minority Ethnic
communities and as a result, more than 3,000 people from these communities have
joined the NHS Organ Donor Register.

26-28 April 2017 | Nottingham 59

LINC Medical Systems Ltd

LINC Medical Systems Ltd is an independent British Company who, for over 19
years, has been an established supplier of renal equipment and devices to the NHS
from its offices, warehouse and service centre in Leicestershire. Our independence
means we can supply what you, the customer needs at competitive prices.

We have a dedicated and friendly team of Customer service personnel, Product
specialists, Clinical nurse specialists and technicians to serve you 365 days a year.

• Veinplicity Vascular access device • AGE Reader
• Hand held Ultra-sound device for • DIMI Home therapies and Cardiac

Vascular access failure device
• HemoDIALERT venous dislodgement • MedVISION Networking and data

alarm management system
• Therapy chairs • ECOmix Acid production system
• Plasma apheresis devices • Joline Dialysis catheters
• Medbike exercise bikes • Peritoneal Dialysis catheters and kits
• Sonoclot POC Heparin management • Asahi Dialysers, Blood lines and Fistula

device needles

Medtronic - Bellco

Bellco has been a pioneer in hemodialysis treatments since 1972, with a mission
to create therapeutic solutions for chronic renal failure and critically ill patients.
They have had a distinct focus on personalized and innovative treatments to meet
complex patient needs.

The acquisition of the Bellco portfolio by Medtronic will be one of the foundations
of Medtronic’s recently formed Renal Care Solution business, furthering Medtronic’s
commitment to improve outcome, expand therapy access and optimize cost and
efficiency.

KIDNEY PATIENTS UK The National Kidney Federation

The National Kidney Federation is unique because, although there are a large
number of kidney charities, the NKF is the national kidney charity actually run by
Kidney Patients for Kidney Patients.

Most Renal units have a Kidney patient Association (KPA) specifically attached to
that unit, however, in 1978 these independent charities realised that they needed
a national organisation to fight their cause as renal provision was in dire difficulties,
overstretched, and under resourced. If ever there was a case of post code provision,
renal disease was it! Currently there are 55 KPAs and they come together as the
controlling Council of the National Kidney Federation, the KPAs are both the ears
and the eyes of the NKF and its controlling force. Patients are the Officers of the
NKF, the Executive Committee of the NKF and the workforce of the NKF. Apart from
eight members of staff, all other personnel are either Kidney patients or carers of
Kidney patients.

Unlike other kidney charities, the NKF has only two roles - campaigning for
improvements to renal provision and treatment, and national patient support
services.

60 British Renal Society Conference

Nikkiso

Nikkiso, a pioneer in Dialysis and Acute Blood Purification, strives to advance
complex medical technologies that optimise patient care in End-stage Renal and
Critical Care areas. Through our commitment to improving clinical efficiency and
the patient experience, Nikkiso has built a global reputation for unparalleled quality
and innovation.

Improving patient outcomes is at the very core of our ethos, balanced with
addressing the needs of caregivers so they can focus on their patients who need our
products.

This is evident in the launch of the DBB-EXA, the first fully automated dialysis system
incorporating our BVM, Haemo-Master and D-FAS.

Nipro

Nipro is one of the world’s largest producers of medical equipment for dialysis
and dialysis related treatments. With over 30 years of continuous research and
development and a dedication to improving the safety and quality of healthcare
we continue to bring products to the market that reflect our customers’ needs
and make healthcare safer. Our renal product range includes dialysis machines,
access flow measurement devices, water treatments systems, concentrate systems,
dialysers, fistula needles, blood tubing sets, haemostatic bandages, bicarbonate
cartridges and catheters.

Our focus on quality and safety does not just stop with our products. Nipro has an
experienced and talented team on hand dedicated to supporting our customers and
providing high quality, effective training and technical support.

So come meet the team on our stand at this year’s BRS conference and learn more
about what we have to offer.

NxStage

NxStage provides the life changing benefits of home haemodialysis to a wider
range of patients than ever before, with a simple, flexible and portable home
haemodialysis therapy solution specifically designed for the patient. NxStage is
more than a company; we are leading the renal revolution. Our innovative products
are helping to shape and transform renal care.

26-28 April 2017 | Nottingham 61

Orphan Europe

Everything we do is driven by the needs of people who have a rare disease:

• Our team shares the conviction that each person with a rare disease has the
right to the best treatment

• We have nearly 27 years experience in bringing orphan drugs to market for rare
diseases: 19 products references sold in 2016 with more in the pipeline

• We help to create, and work alongside, global networks of patients, patient
groups, experts, healthcare professionals, scientists, policy makers and
regulators

• We have around 160 staff in 30 countries, and have plans to expand further
around the world

• We have unparalleled experience around the development of clinical trials for
orphan drugs and in specialist regulatory requirements

• Our infrastructure has been developed for the novel needs of producing,
packaging and distributing very small numbers of specialist products to people
around the world

• Orphan Europe is committed to improving the diagnosis and management of
rare diseases through our educational work and the Recordati Rare Diseases
Foundation.

Otsuka Pharmaceutical

Otsuka Pharmaceutical is a global healthcare company with the corporate
philosophy: ‘Otsuka-people creating new products for better health worldwide.’
The Otsuka Group is comprised of 166 companies and employs approximately
44,000 people globally with products available in more than 80 countries worldwide.
Otsuka is committed to focusing its research and development on innovative
products and medical devices that address unmet medical needs, particularly in
our specialist areas of renal, endocrine, gastrointestinal and central nervous system
disorders.

Pharmacosmos

Pharmacosmos develops and markets medicines for the treatment of iron deficiency.
An independent pharmaceutical company with an ongoing R&D programme, our
goal is to improve iron therapy options for patients and healthcare professionals.

We want to change the way iron deficiency is prevented and treated in humans.

We are inspired by one central question: How can we continue to improve patient
safety, recovery and convenience and thereby achieve better outcomes?

62 British Renal Society Conference

Plinth Medical

Plinth Medical are proud to present our innovative new Column Lift Dialysis
Treatment Couch.

Featuring a safe working load of 250KG (39 Stone) and both Trendelenburg and
Reverse Trendelenburg tilting capability, this market leading new equipment comes
with our unrivalled LIFETIME frame warranty and five year component warranty.

We offer a free no obligation trial of this equipment - please come and find us at
stand N3 to discuss your requirements.

Plinth Medical is the sales and customer service arm of Plinth 2000 the premier
supplier of examination and treatment couches.

We have served our customers needs for over 40 years and continue to develop new
and exciting products focused on the safety of clinical staff.

Quanta

Quanta aims to improve the lives of dialysis patients by providing advanced
haemodialysis solutions for use in the clinic and the home. The Company’s lead product
SC+ provides performance, flexibility and convenience to empower dialysis patients
to regain control of their lives. Founded in 2008 and based in Alcester, UK, Quanta
has attracted funding from a group of leading investors including: Stage Capital/NBGI
Ventures, Wellington Partners, Seroba, b-tov Partners, ALIAD, Seventure Partners and
Kuwait Life Sciences Company, as well as IMI plc.

SC+ supports patients across the continuum of care from the clinic to the home. It is the
only easy-to-use, compact, haemodialysis system offering high performance comparable
to conventional devices and compatible with traditional treatment regimens used in-
centre. The technology behind SC+ is based on an innovative and unique design that
incorporates all fluid management activities onto a single-use disposable cartridge. This
cartridge-based design is intended to reduce downtime, simplify treatment complexity
and reduce the risk of contamination. SC+ has regulatory approval in Europe (CE Mark)
and is currently being used to treat patients in the UK.

The Renal Nutrition Group

The Renal Nutrition Group (RNG) is a specialist interest group of the British Dietetic
Association (BDA). It has a membership of over 300 registered dietitians who work
or have an interest in the specialist field of renal nutrition through clinical practice or
research. The RNG promotes the role of the renal dietitian in the multidisciplinary
team to service users and healthcare professionals and acts as the source of national
expertise in renal nutrition. Established in 1970, it is committed to delivering
accurate, comprehensive information to facilitate standardised practice and
demonstrate clinical effectiveness in the UK.

The RNG won BDA Specialist Group of the Year in 2016 and is a dynamic group;
delivering expert advice and encouraging the sharing of practice to meet the needs
of the diverse roles of the renal dietitian via online group discussions, evidence
based resources, audit databases, research, business meetings, professional
development days and courses

26-28 April 2017 | Nottingham 63

Renal Services

Renal Services (UK) Ltd is a leading independent provider of dialysis services, operating
an expanding network of dialysis units across the UK. We work closely with the NHS
to deliver the highest level of care in the most comfortable environment. Our units are
designed, commissioned and managed with patient experience, choice and outcomes as
our primary objectives.

Our central management team members have all spent time working within the dialysis
industry as nurses, doctors, managers and directors – they therefore bring together a
wealth of knowledge which complements the delivery of our services and inspired patient
care. The executive team’s experience in dialysis services has resulted in a unique concept
of renal care centred on the patient experience and is the only nurse led company in this
sector in the UK.

Shire UK

Shire UK is an indirect wholly owned subsidiary of Shire plc, a global specialty
biopharmaceutical company that works closely with specialist physicians, nurses,
pharmacists and other healthcare professionals to develop and market medicines
that improve quality of life for patients, their families and carers.

Shire UK currently focuses on the following therapeutic areas:

• Alzheimer’s Disease • Fabry Disease
• Attention Deficit Hyperactivity • Gaucher’s Disease
• Hereditary Angioedema
Disorder (ADHD) • Hunter Syndrome
• Chronic Constipation • Seizures and Epilepsy
• Chronic Kidney Disease • Ulcerative Colitis
• Essential Thrombocythaemia

64 British Renal Society Conference

Stanningley Pharma

Stanningley Pharma is pleased to be supporting the BRS Conference and to be
providing 5 renal products for healthcare professionals.

This year Stanningley Pharma has seen the launch of Renapro® Shots that are
complementary to the existing Renapro® powder. These products provide a way
offering renal patients a high protein nutritional supplement with minimal amounts
of phosphate, potassium and fluid.

Renavit® has become an established product for the replacement of water soluble
vitamins that are removed by the dialysis process. This simple, once daily regimen
is in line with the European Best Practice Guidelines and the Renal Association
Guidelines.

The NICE guideline for the management of hyperphosphataemia has positioned
Calcium Acetate as the first line drug treatment. Stanningley Pharma has provided a
preparation that addresses many of the issues previously associated with taste and
tablet size.

Maintaining vascular access and successful maturation of AV fistula continues to
be a challenge with dialysis patients. Stanningley pharma now has good data to
support the use of Far Infrared during both maturation and maintenance of fistulas.
Many renal units in the UK are now using Far Infrared, and there are posters at the
conference reporting these good results

The ongoing achievements of Stanningley Pharma in 2016/17, and the adoption of
new products demonstrate the company’s commitment to innovation and the wider
renal community.

Suez

In the face of global challenges and an ever changing world, the SUEZ Group strives
daily to deliver essential life services, to protect water resources, and to treat and
recover waste; and thus support our customers by providing innovative solutions.

In this developing world, where natural resources are limited, we must promote
a more rational use of natural resources, as rapid urbanisation and a growing
population mean we will need to optimise our use of resources and reduce our
consumption of raw materials.

Consequently our strategy consists of promoting an effective and sustainable
management of resources and of developing the production of new resources to
anticipate demand.

26-28 April 2017 | Nottingham 65

Syner-Med

Syner-Med (PP) Ltd has been bringing innovative pharmaceutical products and
medical devices to healthcare professionals and patients for over 20 years.
Currently the Company is focused on the management of central venous catheters
helping our customers to manage occlusions and reduce infections.
Syner-Med is committed to providing healthcare professionals with education,
enabling them to deliver evidence based patient care and to use our products as
cost effectively as possible.
On our stand we have -
Syner-Kinase® (urokinase): the only thrombolytic licensed for catheter locking and
for infusion through the catheter. Syner-Kinase® is also free of human albumin.
Citra-Lock™S (trisodium citrate): Anticoagulant and Antimicrobial. A range of pre-
filled syringes containing trisodium citrate catheter locking solution available in 4%,
30% & 46.7%.
Citra-Valve™: Needle-free catheter connectors developed to reduce handling and
infection. Suitable for patients undergoing haemodialysis.
DualCap Solo™: Disinfection caps for needle-free catheter connectors containing
sponge with 70% isopropyl alcohol (IPA).
Please visit stand F3 to see what’s new in Catheter Management.

Terumo BCT

Terumo BCT is a global leader in blood component, therapeutic apheresis and
cellular technologies.
We are committed to advancing apheresis through innovation in plasmapheresis
using centrifugal technology.
Our collaboration with customers helps enable the best possible procedures today,
increase the number of clinicians who adopt these procedures,
identify new uses for apheresis and develop next-generation procedures — all for
the patients we ultimately serve.

66 British Renal Society Conference

The UK Renal Registry

Working in partnership with the renal community to improve patient care through
audit, research and quality improvement programmes”
The UK Renal Registry (UKRR) is part of the Renal Association, a not for profit
organisation registered with the Charity Commission (Registered in England No.
2229663).

We are recognised as having one of the very few high quality clinical databases
open to requests from researchers. The UKRR collects, analyses and reports on data
from 71 adult and 13 paediatric renal centres. Participation is mandated in England
through the NHS National Service Specification and the Chief Executive of each
Trust is responsible for adherence to this contract.

We will be featuring the work of Think Kidneys during the conference.

Think Kidneys national programmes are led by the renal community and the UK
Renal Registry. We are currently promoting three programmes:-

• Acute Kidney Injury
• Chronic Kidney Disease
• Kidney Quality Improvement Partnership

Please visit stand B1 where we can share the latest news on all three programmes
with you.

Veolia Water Technologies UK

Veolia Water Technologies UK is part of Veolia, which is one of the world’s major
providers of technical solutions and facilities for water treatment. (Large Text)

Veolia Water Technologies UK specialises in supplying innovative process solutions
for dialysis and we are the exclusive distributor to the UK and Ireland for the full
range of renal products from DWA, the German dialysis specialist.

We understand the issues and key challenges dialysis facilities face in delivering a
high quality, reliable and cost-effective service for their patients. Our many years
of experience and expertise enable us to offer you innovative and proven solutions
to help you at every stage in the project from initial consultation and system
specification to installation and ongoing service and support. Furthermore we have a
track record for delivering projects on time and on budget.

26-28 April 2017 | Nottingham 67

Vifor Fresenius Medical Care Renal Pharma UK

Vifor Fresenius Medical Care Renal Pharma UK, established in November 2015,
is a pharmaceutical company specialising in Nephrology. The company is a joint
operation between Vifor Pharma (a company of the Galenica Group) and Fresenius
Medical Care.

Vifor Pharma is a world leader in the discovery, development, manufacturing and
marketing of pharmaceutical products for the treatment of iron deficiency, and
Fresenius Medical Care is the world’s leading provider of dialysis services and
products.

Since 2010, Vifor Fresenius Medical Care Renal Pharma has been operating as
a common company working in partnership with our customers and supplying
our leading brands of intravenous iron and introducing our latest product, a non-
calcium, iron based phosphate binder to support renal patient needs.

Our vision is to be the customers’ partner of choice for renal pharmaceuticals and
innovative patient-centric solutions. We have a strong pipeline focused on helping
improve the lives of the growing numbers of patients around the world who suffer
from chronic kidney disease (C.K.D.).

Whitewater

Whitewater is a leading supplier of water purification plants for over 85 years.
Providing state of the art ultrapure dialysis water treatment plants for renal dialysis
centres (to the Renal Associations Guidelines) for over 20 years. Our Technical
experience and expertise in designing renal dialysis water systems and preventative
maintenance service with guaranteed 24/7 ‘on call’ contribute to 100% customer
reassurance.

Site specific service contracts can be arranged with Whitewater. Servicing
equipment and support is provided by Whitewater’s specialist team of service
technicians operating to the ISO9001:2008, ISO 14001:2015 / OHSAS 18001:2007
quality standards.

Whitewater projects department will work with your hospital’s engineering team
and provide a bespoke engineered system with the highest levels of interactive
monitoring and archiving for ‘day to day’ critical parameters, including remote
diagnostic and interrogation facilities.

As new technological advancements continues, part of Whitewater’s standard supply
include cost, energy and space saving, as well as green technologies and as part of
this innovation, all Whitewater RO’s can be operated at 90% recovery.

The Whitewater ethos is to operate and interact with all our stakeholders to the
highest levels of integrity and all the Whitewater team is committed to these values.

68 British Renal Society Conference

Notes

26-28 April 2017 | Nottingham 69

Notes

70 British Renal Society Conference

Notes

26-28 April 2017 | Nottingham 71

BRS

British Renal Society

Multi-professional working